CareDx Inc - Asset Resilience Ratio
CareDx Inc (CDNA) has an Asset Resilience Ratio of 26.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check CareDx Inc strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how CareDx Inc's Asset Resilience Ratio has changed over time. See CDNA net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down CareDx Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CareDx Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $109.25 Million | 26.58% |
| Total Liquid Assets | $109.25 Million | 26.58% |
Asset Resilience Insights
- Very High Liquidity: CareDx Inc maintains exceptional liquid asset reserves at 26.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CareDx Inc Industry Peers by Asset Resilience Ratio
Compare CareDx Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for CareDx Inc (2012–2025)
The table below shows the annual Asset Resilience Ratio data for CareDx Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 27.05% | $111.78 Million | $413.23 Million | -2.67pp |
| 2024-12-31 | 29.72% | $145.96 Million | $491.05 Million | -3.10pp |
| 2023-12-31 | 32.82% | $153.22 Million | $466.83 Million | -4.59pp |
| 2022-12-31 | 37.42% | $203.17 Million | $542.99 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $566.62 Million | -- |
| 2020-12-31 | 24.43% | $90.03 Million | $368.51 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $83.56 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $76.73 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $55.64 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $61.14 Million | -- |
| 2012-12-31 | 0.30% | $30.00K | $9.88 Million | -- |
About CareDx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart tr… Read more